

## The Hugh A. Sampson Food Allergy Lectureship



Hugh A. Sampson, MD is the Kurt Hirschhorn Professor of Pediatrics, the Dean for Translational Biomedical Research and the Director of the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai in New York. Dr. Sampson has over 30 years' experience in translational research focusing on food allergic disorders and basic immunologic mechanisms responsible for these disorders.

His research has been funded continuously by a number of grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, including being the Principal Investigator for the Consortium for Food Allergy Research.

He has published over 450 articles, 80 book chapters and edited 5 books, primarily on clinical and immunopathogenic aspects of food allergic disorders and chaired working groups that produced standardized criteria for diagnosing anaphylaxis, the Practall guidelines for conducting double-blind placebo-controlled oral food challenges and the most recent Joint Council Practice Parameters on Food Allergy.

Some of Dr. Sampson's accomplishments in research include being the first to describe food allergy as a trigger for eosinophilic esophagitis, to use foods under an IND in oral immunotherapy trials, the ability of most milk-allergic children to tolerate heat-denatured (baked) milk products, and among the first to clearly delineate the relationship of atopic dermatitis and food allergy.

He also co-developed novel approaches to therapy including Traditional Chinese medicine and mutated proteins with adjuvant. His laboratory also identified factors to improve food allergy diagnostics, such as the correlation between quantitative IgE levels and probability of allergic reactivity, and analysis of allergenic component proteins and epitopes. Thompson Reuters recognized Dr. Sampson as among the "World's Most Influential Scientific Minds 2014", a distinction indicating the top 1% of researchers with the most cited documents in their specific field. He was elected to membership in the Institute of Medicine of the National Academies in 2003 for his research accomplishments.

Dr. Sampson is past chair of the Section on Allergy & Immunology of the American Academy of Pediatrics and the past-president of the American Academy of Allergy, Asthma and Immunology. His service to the AAAAI also includes having been Chair of 4 Committees/Sections and membership on 8 Sections, Committees or subcommittees.

Additional service to our specialty includes his being on the Editorial Board of 5 allergy Journals and serving 20 years on the JACI Editorial Board, being Chair of the Medical Advisory Board for FAAN/FARE for 25 years, and a Director on the American Board of Allergy and Immunology. Dr. Sampson is proud to have been a Training Program director for over 15 years, and mentoring >30 trainees, many of whom are leaders in the field. Dr. Sampson is consistently recognized by Castle Connolly as among America's top doctors.

**2018 marks the 3<sup>rd</sup> year of the Hugh A. Sampson Food Allergy Lectureship. It will be presented in Symposium Session 3305: New Developments in Atopic Dermatitis and Implications for the Atopic March on Sunday, March 4, 2018: 10:45 am to 12:00 pm, Convention Center, South Concourse, Level 3, S320CD.**

## **The Hugh A. Sampson Food Allergy Lectureship – Emma Guttman-Yassky, MD PhD**



Emma Guttman-Yassky, MD, PhD, the Sol and Clara Kest professor of dermatology, is vice chair for research at the department of dermatology, director of the Center for Excellence in Eczema, and the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai Medical Center, New York.

She earned her M.D. from Sackler in Tel-Aviv, and a Ph.D. from Bar-Ilan, Israel. After her Israeli Board certification in dermatology, Dr. Guttman moved to the U.S. to pursue a postdoctoral fellowship at The Rockefeller University and a second dermatology residency at Weill-Cornell, NY.

Dr. Guttman's major focus is atopic dermatitis/AD. She made paradigm-shifting discoveries on the immunologic basis of AD in humans, enriching the understanding of its pathophysiology, opening the door to new therapeutics.

Dr. Guttman has developed comprehensive molecular maps of AD, defining skin differentiation and immune-circuits characterizing this disease. She has established the reversibility of the AD phenotype and defined a series of biomarkers that are now accelerating testing of novel pathway-specific drugs for AD.

She is now testing (both clinically and mechanistically) multiple targeted therapeutics for atopic dermatitis that target Th2, Th22, and Th17/IL-23 axis. She has recently also extended her research interest to alopecia areata in which her findings are also translated to possible novel therapeutic targets.

She has co-founded the international eczema council/IEC, for which she functions as president-elect. She was elected to the American Society for Clinical Investigation/ASCI, the American Dermatological Society/ADA, and received the Young Investigator Award (2011) from the AAD.